Peter Andreana

Dr. Peter Andreana

University of Toledo, Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, 2801 W. Bancroft St., Wolfe Hall 2232B, Toledo, OH 43606-3390, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FHFarzana Hossain
Farzana Hossain
Peter AndreanaPeter Andreana
Peter Andreana
Cancer cells of diverse origins express extracellular tumor-specific carbohydrate antigens (TACAs) because of aberrant glycosylation. Overexpressed TACAs on the surface of tumor cells are considered biomarkers for cancer detection and have always been prioritized for the development of novel carbohydrate-based anti-cancer vaccines. In recent years, progress has been made in developing synthetic, carbohydrate-based antitumor vaccines to improve immune responses associated with targeting these specific antigens. Tumor cells also exhaust more energy for proliferation than normal cells, by consuming excessive amounts of glucose via overexpressed sugar binding or transporting receptors located in the cellular membrane. Furthermore, inspired by the Warburg effect, glycoconjugation strategies of anticancer drugs have gained considerable attention from the scientific community. This review highlights a small cohort of recent efforts which have been made in carbohydrate-based cancer treatments, including vaccine design and the development of glycoconjugate prodrugs, glycosidase inhibiting iminosugars, and early cancer diagnosis.

13 August 2021 in ACS Central Science
Verified
Journal Article
Open access
Peter AndreanaPeter Andreana
Peter Andreana
DCDavid Crich
David Crich
The complexity and irreproducibility of glycosylation reactions retard progress in the glycosciences. Application of the steady-state hypothesis to transient oxocarbenium ion–counterion pair interm... With a view to reducing the notorious complexity and irreproducibility of glycosylation reactions, 12 guidelines for the choice of concentration, temperature, and counterions are adumbrated.

20 May 2016 in Vaccines
Verified
Journal Article
Open access
PDF file
SNSharmeen Nishat
Sharmeen Nishat
Peter AndreanaPeter Andreana
Peter Andreana
Carbohydrates are regarded as promising targets for vaccine development against infectious disease because cell surface glycans on many infectious agents are attributed to playing an important role in pathogenesis. In addition, oncogenic transformation of normal cells, in many cases, is associated with aberrant glycosylation of the cell surface glycan generating tumor associated carbohydrate antigens (TACAs). Technological advances in glycobiology have added a new dimension to immunotherapy when considering carbohydrates as key targets in developing safe and effective vaccines to combat cancer, bacterial infections, viral infections, etc. Many consider effective vaccines induce T-cell dependent immunity with satisfactory levels of immunological memory that preclude recurrence. Unfortunately, carbohydrates alone are poorly immunogenic as they do not bind strongly to the MHCII complex and thus fail to elicit T-cell immunity. To increase immunogenicity, carbohydrates have been conjugated to carrier proteins, which sometimes can impede carbohydrate specific immunity as peptide-based immune responses can negate antibodies directed at the targeted carbohydrate antigens. To overcome many challenges in using carbohydrate-based vaccine design and development approaches targeting cancer and other diseases, zwitterionic polysaccharides (ZPSs), isolated from the capsule of commensal anaerobic bacteria, will be discussed as promising carriers of carbohydrate antigens to achieve desired immunological responses.

21 October 2016 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MSMengchao Shi
Mengchao Shi
KKKristopher A. Kleski
Kristopher A. Kleski
KTKevin R. Trabbic
Kevin R. Trabbic
JBJean-Paul Bourgault
Jean-Paul Bourgault
Peter AndreanaPeter Andreana
Peter Andreana

29 January 2014 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
JBJean Paul Bourgault
Jean Paul Bourgault
KTKevin R. Trabbic
Kevin R. Trabbic
MSMengchao Shi
Mengchao Shi
Peter AndreanaPeter Andreana
Peter Andreana
The α-aminooxy derivative of the Thomsen–Friedenriech tumor associated carbohydrate antigen has been synthesized in 11 steps utilizing a D-GalN3 acceptor carrying a pre-installed α-N-hydroxysuccinimidyl moiety. The natural α linkage was prepared in high selectivity employing a suitably protected D-GalN3-thioglycoside donor with N-hydroxysuccinimide. With access to α-TF-ONH2, the preparation of the TF-PS A1 vaccine candidate ensued smoothly through oxime bond formation.